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Abstract
Background: Amyotrophic Lateral Sclerosis (ALS) is a devastating neurological disorder characterized by selective
degeneration of upper and lower motor neurons. The primary triggers for motor neuron degeneration are unknown but
inflammation, oxidative stress and mitochondrial defects have been identified as potential contributing factors. Metformin is
an anti-type II diabetes drug that has anti-inflammatory and anti-oxidant properties, can bring about mitochondrial
biogenesis and has been shown to attenuate pathology in mouse models of Huntington’s disease and multiple sclerosis. We
therefore hypothesized that it might increase survival in the SOD1
G93A murine model of ALS.
Methodology/Principal Findings: Treatment of male and female SOD1
G93A mice (n=$6 per sex) with 2 mg/ml metformin
in the drinking water from 35 days, resulted in a significant increase in motor unit survival, as measured by in vivo
electrophysiology at 100 days, in male EDL muscles (24+/22 vs. 14+/22 motor units, p,0.005) and female TA muscles (21+/
21 vs. 15+/22 motor units, P=0.0134). We therefore continued to test the effect of 0.5, 2 and 5 mg/ml metformin in the
drinking water from 35 days on disease onset and progression (identified by twice weekly determination of weight and
neurological score) as well as survival in male and female SOD1
G93A mice (n=$14 per sex). Results for all groups were
compared using Kaplan-Meier time to event analyses. In this survival study, metformin was unable to reduce pathology at
any dose and had an unexpected dose-dependent negative effect on the onset of neurological symptoms (P=0.0236) and
on disease progression (P=0.0362) in female mice.
Conclusions/Significance: This study suggests that metformin is a poor candidate for clinical trial in ALS patients and that
the possibility of harmful effects of metformin in female ALS patients with type II diabetes should be investigated.
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Introduction
Amyotrophic Lateral Sclerosis (ALS [OMIM 105400]) is a fatal
neurodegenerative disorder associated with the selective degener-
ation of upper and lower motor neurons, for which there are
currently no effective therapeutics [1]. Although the majority of
ALS cases are sporadic, approximately 10% have a familial origin
and of these 15–20% are caused by gain of function mutations in
the copper/zinc superoxide dismutase (SOD1) gene (OMIM
147450) [2]. The primary triggers for motor neuron degeneration
in ALS remain elusive, however research in patients and mutant
SOD1 based models has revealed several processes that are likely
to contribute to pathology, including but not limited to:
inflammation and toxic glial activation [3,4], mitochondrial
dysfunction [5] and oxidative stress[3,5].
Metformin is a small molecule activator of the metabolic
regulator, AMP-activated protein kinase (AMPK) (OMIM num-
bers: a1 subunit 602739, a2 subunit 600497, b1 subunit 602740,
b2 subunit 602741, c1 subunit 602742, c2 subunit 602743), which
is routinely used for the treatment of type II diabetes [6,7].
Metformin was originally prescribed for diabetes on the basis of its
ability to reduce hepatic glucose production and increase insulin
sensitivity [8], but it has subsequently been found to have potent
anti-inflammatory [9,10,11] and antioxidant [11,12,13] properties
as well as the ability to bring about mitochondrial biogenesis [14]
and to cross the blood brain barrier (BBB) [15,16]. Metformin
therapy has been successfully tested in mouse models of both
Huntington’s disease (OMIM 143100) and multiple sclerosis
(OMIM 126200), in which, like in ALS, inflammation, oxidative
stress and mitochondrial defects are thought to be contributing
factors to pathology [17,18] Specifically, oral administration of
metformin has been shown to increase lifespan and improve motor
performance in male mice in the R6/2 model of Huntington’s
disease [16] and to attenuate pathology and inhibit the expression
of pro-inflammatory mediators in the murine Experimental
Autoimmune Encephalomyelitis (EAE) model of multiple sclerosis
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therapy in these disease models of neurodegeneration, we
hypothesised that metformin therapy would also attenuate motor
neuron degeneration in the SOD1
G93A mouse model of ALS [20].
We performed initial investigations in which chronic treatment
with 2 mg/ml metformin in the drinking water from 35 days of
age, led to decreased motor unit loss in the hindlimbs of both male
and female SOD1
G93A mice at 100 days of age (an early symp-
tomatic time point [21]) Consequently, we performed a blinded,
high powered, dose response survival study, using an optimised
study format developed by the ALS Therapy Development
Institute (ALSTDI) [22], to assess the effect of chronic metformin
treatment on disease onset, progression and survival in SOD1
G93A
mice. Surprisingly, metformin had no beneficial effects in male or
female mice and furthermore, had a negative effect on the onset of
neurological symptoms and disease progression in female mice.
Materials and Methods
Ethics Statement
All animal experiments were carried out under license from the
Home Office (UK) in accordance with The Animals (Scientific
Procedures) Act 1986 and were approved by Imperial College/
Royal Veterinary College ethical committees (note: neither body
provides an approval number).
Mouse breeding and maintenance
For all experiments, mice were housed in a minimal disease
facility, with a 12:12 hour light: dark cycle and food and either
water or metformin solution ad libitum. Male mice overexpressing
human SOD1 with the ALS-causing G93A mutation [B6SJL-TgN
SOD1
G93A) 1 Gur/J, Stock number 002726] [20] were originally
purchased from the Jackson Laboratory (Bar Harbor, ME). They
were subsequently maintained (for over 25 generations), as
hemizygotes through breeding with wild-type F1 hybrid C57Bl/
66CBA/Ca females. Mice on this background [23] have similar
lifespans [24,25] and disease progression characteristics (as
measured by hindlimb electrophysiological parameters) [23,26],
to mice on the original B6SJL background and no changes in
disease progression or lifespan have been seen with successive
generations in our laboratory.
Genotyping and copy number assessment
SOD1
G93A mice were genotyped by PCR from an ear biopsy
using the following primers: forward: 59-CATCAGCCCTAATC-
CATCTGA-39 and reverse: 59-CGCGACTAACAATCAAAG-
TGA-39. Following death, a tail tip was taken from all experi-
mental mice for potential copy number assessment via real time
quantitative PCR (Q-PCR) as previously described by Alexander
et al., [27]. Copy number assessment was performed for all mice
used for motor unit quantification and any mice showing an
outlying disease time course in our survival study. Mice showing
copy number loss were excluded. Genotyping and copy number
assessment protocols are described in detail in the supporting
information (Method S1).
Motor unit quantification study
Metformin treatment. Male and female SOD1
G93A mice
were supplied with either normal drinking water or a solution of
2 mg/ml metformin in the drinking water from 35 days of age.
Solutions were changed weekly. At 100 days of age (+/22 days),
the number of functional motor units present in the right Tibialis
Anterior (TA) and Extensor Digitorum Longus (EDL) muscles of
both treated and control mice was analysed via in vivo electrophy-
siology as described below. A minimum of 6 mice per sex were
used in both the control and treatment groups in this study.
Motor unit assessment via in vivo electrophy-
siology. This method is routinely performed in our laboratory
and has been previously described [23,28]. Mice were deeply
anesthetized via intra peritoneal injection of fentanyl/fluanisone
(Hypnorm, Vetapharma Ltd.), midazolam (Hypnovel, Roche) and
water (1:1:2 by volume) at a dosage of 9 ml/kg. Careful
monitoring of mice was performed throughout the experiment
and additional doses of anaesthetic were administered as required
to ensure that there was no reflex response to toe pinch. The distal
tendons of the right TA and EDL muscles were dissected free from
surrounding tissue, individually tied with 4.0 braided surgical silk
(Interfocus) and cut at their distal ends. The sciatic nerve was then
exposed and all its branches cut except the common peroneal
nerve (CPN), which innervates the TA and EDL muscles. The
mouse was placed on a thermopad (Harvard Apparatus) to
maintain body temperature at 37uC. The right foot was secured to
a platform and the knee immobilized using a stainless steel pin.
The TA and EDL muscle tendons were then individually attached
to a strain gauge (Dynamometer, UFI Devices) to record muscle
twitch forces. Isometric twitch contractions were elicited by
stimulating the distal part of the DPN via bipolar silver
electrodes using square wave pulses of 0.02 ms. Force output
from the strain gauge was recorded using an analogue to digital
converter interfaced with a computer running the appropriate
software (Cambridge Electronics Design Ltd). The stimulation
voltage and subsequently the length of the muscle were adjusted to
produce the maximum isometric twitch force. The stimulus
amplitude was then set to 0 V and manually increased over a
range of 10 V, which resulted in discrete increments in twitch
force due to the successive recruitment of motor units. With each
increment in force, the stimulus amplitude was held at constant
voltage for at least 5 stimuli and then increased manually until a
larger twitch was generated. This procedure was repeated until
there was no further increase in force, indicating that all motor
units were recruited. The number of step-wise increments of force
was counted for both control and metformin-treated mice in a
blinded fashion and taken as an estimate of the number of motor
units in the TA and EDL muscles.
Statistical analyses. After testing the data for normality, the
number of surviving motor units in the TA and EDL muscles
respectively of treated vs. non-treated male mice and treated vs.
non-treated female mice were compared using individual unpaired
t-tests.
Dose-response survival study
Experimental groups. Twenty breeding trios each
consisting of one SOD1
G93A transgenic male and two F1 hybrid
C57B1106CBA/Ca females were set up simultaneously to
generate a large cohort of 286 age matched pups to provide
SOD1
G93A mice for enrolment in the survival study. Females were
separated when pregnant to allow tracking of the lineage of
resultant litters. Following genotyping and when the resultant male
and female SOD1
G93A pups reached 35 days of age (+/22 days),
they were separated into four groups which were balanced with
respect to age (+/22 days), gender (14 males and 15 females per
group) and body weight within gender (mean starting weights for
all groups were within 0.5 g of each other). In order to ensure
consistency in genetic background across the groups, transgenic
mice from each litter were distributed evenly between the four
groups in a gender specific fashion. Mice were housed within their
groups in cages of either 4 or 5 mice for males and 5 mice for
females.
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5 mg/ml metformin in the drinking water from 35 days of age.
Metformin solutions were freshly prepared in sterilised bottles and
changed twice weekly. Control mice received normal drinking
water throughout the experiment. The identities of control and
treatment groups were blinded to animal technicians and the
investigator and were only revealed once all data analysis had been
completed. When mice reached 100 days of age and began to
show neurological symptoms, cages were fitted with long sipper
tubes (Techniplast, UK) to allow easy access to water/drug
solution and mice were provided daily with a standard amount of
mashed diet prepared with the relevant water/drug solution. Dry
food pellets were left on the bedding in addition to in the food
hoppers throughout the experiment and cage conditions including
bedding and enrichment were kept consistent across groups.
Analysis of disease progression and survival. Neurolo-
gical scores for both hind limbs were assessed twice weekly for
each mouse from 41 days of age. Neurological scores were
assigned using a scale of 0–4 developed by the ALSTDI through
detailed observations of SOD1
G93A mouse pathology [22,29,30].
Criteria used to assign each score level were:
0 - Full extension of hind legs away from lateral midline when
mouse is suspended by its tail and mouse can hold this for
2 seconds, suspended 2–3 times.
1 - Collapse or partial collapse of leg extension towards lateral
midline (weakness) or trembling of hind legs during tail suspension.
2 - Toes curl under at least twice during walking of 12 inches or
any part of foot is dragging along cage bottom (a clean cage
containing no bedding was used for this analysis to permit easy
viewing of the toes).
3 - Rigid paralysis or minimal joint movement, foot not being
used for forward motion.
4 - Mouse cannot right itself within 30 s from one or both of its
sides (this test was performed in a clean cage containing the same
type and amount of bedding as present in the mouse’s home cage).
Body weight for all mice was measured twice weekly from 35
days of age. This provided an additional, non-invasive, measure of
disease onset and progression and also allowed monitoring of the
general health of the mice. Weight-loss in high copy SOD1
G93A
mice is normally a gradual process that begins at approximately 90
days of age and continues until death. Rapid losses of weight over
a short number of days that do not fit the normal pattern can
therefore be indicative of non-ALS related or drug-induced
maladies [22].
For humane reasons, a uniform end point of the inability of a
mouse to right itself within 30 s of being placed on a side
(neurological score 4) was employed for all mice. From 100 days of
age, the righting reflex of each mouse from each side was tested
twice daily to ensure that the end point of each mouse was
accurately determined. Once mice reached their end point, they
were euthanized via cervical dislocation and the date and cause of
their death was recorded.
Graphical representation of data and statistical
analyses. As the time course of pathology in male and female
SOD1
G93A mice has been shown to be different [31] and
administered therapeutics may behave differently in male and
female systems, all graphical representations and statistical
analyses were performed separately for males and females. In
order visualise overall changes in body weight and neurological
score, mean body weight and mean neurological score were
plotted for each group over time until the time point at which the
last mouse in the group died. To prevent decomposition of mean
weight and neurological score values as mice reached their end
stage, final weight and neurological score values for individual
mice were carried forward until the time point at which the last
mouse in their group died. This is a practice routinely used when
performing survival analyses with longitudinal monitoring of
weight and neurological score [29,30]. In order to avoid the loss of
statistical validity that can occur when performing repeated
analyses on correlated serial measurements for the same
subjects, we selected relevant summary measures for weight and
neurological score data as advised by Matthews, et al. [32] and
performed statistical analyses on these. Summary measures
selected were time to attain peak weight (the earliest indicator of
disease onset), time from peak weight to death (an indicator of
disease progression), time to attain a neurological score of 2 in
both hind limbs (defined as the definitive onset of symptomatic
neurological disease) and finally time to reach a score of 4 (the
uniform end point selected for this study, which was taken to
represent survival). These summary measures all represent ‘time to
event measures’ and were analyzed using Kaplan Meier survival fit
analyses and the Logrank test for statistical significance. This test
investigates the null hypothesis that the Kaplan Meier curves for
all groups are identical (i.e. that the treatment did not change the
time taken to reach the event being analysed). Low P-values are
therefore indicative of differences between curves that did not
occur due to chance. As multiple groups were being compared and
they could be arranged in order of increasing metformin dose
(from 0 mg/ml metformin in the control group to 0.5 mg/ml then
2 mg/ml then 5 mg/ml), we were also able to compare groups
using the log rank test for trend. This test generates a P-value for
the null hypothesis that there is no linear trend between group
order and median time to event. Low P-values are therefore
indicative of a significant trend between increasing metformin dose
and the event being analysed. The threshold for significance for all
analyses was set at P,0.05. In order to establish the age at which
each mouse reached its peak weight, successive weight values for
each mouse were subjected to spline smoothing and the time at
which the maximum of the weight curve occurred was recorded. If
the smoothed body weight curve for an individual mouse had
multiple equal peaks, the time point at which the final peak
occurred was taken. Spline smoothing of weight curves as well as
all Kaplan Meier survival analyses were carried out using
Graphpad Prism 5 software.
Results
Effect of chronic metformin treatment on motor unit
number at 100 days of age
In order to investigate the potential of metformin treatment for
the attenuation of pathology in SOD1
G93A mice, we examined the
effect of treatment of male and female SOD1
G93A mice with
2 mg/ml metformin in the drinking water (from 35 days of age) on
motor unit survival in the right TA and EDL muscles at 100 days
of age. The dose of 2 mg/ml metformin was selected as it had
previously been shown to be successful in male mice in a model of
Huntington’s disease [16]. Motor unit survival in the muscles
analysed was established by stimulating the right sciatic nerve of
terminally anesthetised mice with pulses of increasing intensity and
counting the number of resultant stepwise increments in twitch
tension, which represented the successive recruitment of motor
axons. Representative traces from these assessments are shown in
Figure 1A and 1B. In these experiments, we observed a small but
significant increase in the survival of functional motor units in the
EDL muscles of metformin treated male SOD1
G93A mice
compared to their untreated counterparts (24+/22 vs. 14+/22
motor units respectively, p,0.005) (Figure 1C) and a trend
towards increased motor unit survival in the EDL muscles of
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G93A mice compared to their
untreated counterparts (22+/22 vs. 16+/22 motor units
respectively, P=0.056) (Fig. 1C). A small but significant increase
in motor unit survival was also seen in the TA muscles of
metformin-treated female SOD1
G93A mice compared to untreated
female SOD1
G93A mice (21+/21 vs. 15+/22 motor units
respectively, P=0.0134) (Fig. 1D) and although there was a strong
trend towards increased motor unit survival in the TA muscles of
metformin-treated male SOD1
G93A mice compared to their
untreated counterparts (20+/24 vs. 16+/22 motor units
respectively), this did not reach significance (Fig. 1D). As a
significant beneficial effect was seen in both male and female mice,
we decided to further test the therapeutic potential of metformin in
SOD1
G93A mice by performing a dose-response survival study.
Dose response survival study
Metformin treatment had no effect on disease onset,
progression or survival in male mice. Four groups of 14
male mice that were balanced for age, litter and body weight were
enrolled in this study. The average starting bodyweights for each
group were within 0.5 g of each other (Control: 20.7 g, 0.5 mg/
ml: 20.5 g, 2 mg/ml: 20.2 g and 5 mg/ml: 20.6 g). During the
study one male from the control group and one male from the
0.5 mg/ml group were found dead prior to developing any
neurological symptoms. Additionally, one male from the 0.5 mg/
ml group developed a kidney cyst and was therefore culled
prematurely. These mice were all recorded as dying from ‘non
ALS deaths’ and were treated as ‘censored’ in Kaplan Meier
analyses and excluded from weight and neurological score plots.
Two males from the 2 mg/ml group sustained fighting wounds
prior to reaching end stage and were culled for humane reasons.
Weight and neurological score data from these mice were included
up to the date at which they were culled in weight and
neurological score plots and they were treated as censored in
Kaplan Meier analyses that required information about end
points.
High copy SOD1
G93A mice, unlike wild type (WT) mice are
unable to maintain body weight from approximately 90 days of
age and steadily lose weight from this time point until death.
Longitudinal monitoring of weight therefore provides a good
indication of disease onset and progression and can reveal
important information about the efficacy of potential therapeu-
tics [22]. The change in mean body weight over time of male
mice in all four groups is plotted in Figure 2A from 35 days
onwards. Weight curves for male mice in all groups showed a
very similar shape with the onset of weight decline, occurring at
,90 days in each group. Consequently, no significant differ-
ences were observed in the selected summary measures of time
to peak weight (Figure 2B, Table 1) and time from peak weight
to end stage (Figure 2C, Table 1). However mice in all treatment
groups appeared to be lighter throughout the study than control
mice.
Figure 1. Effect of metformin treatment on motor unit number in male and female SOD1
G93A mice. Representative traces for in vivo
motor unit assessment protocol (A) untreated SOD1
G93A male Extensor Digitorum Longus (EDL) muscle and (B) metformin treated SOD1
G93A EDL
muscle at 100 days of age. (C) Graph showing mean number of motor units surviving in the EDL muscles of control (SOD1) and metformin treated
(SOD1 tx.) SOD1
G93A mice at 100 days of age (SOD1
G93A male vs. metformin treated SOD1
G93A male, P=0.005 (**)), (SOD1
G93A female vs. metformin-
treated SOD1
G93A female, P=0.056) (D) graph showing mean number of motor units surviving in the Tibialis Anterior (TA) muscles of control (SOD1)
and metformin treated (SOD1 tx.) SOD1
G93A mice at 100 days of age (SOD1
G93A female vs. metformin-treated SOD1
G93A female, P=0.0134 (*)). Error
bars in (C) and (D) represent standard error of the mean (SEM). n=7 SOD1 males, n=6 SOD1 females, n=9 metformin treated SOD1 males and n=15
metformin treated SOD1 females.
doi:10.1371/journal.pone.0024189.g001
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unbiased assessment by the investigator of disease onset, progression
and severity of paralysis in SOD1
G93A mice [22,29]. We found this
scoring system easy to implement and each score to be clearly distinct
from all others, therefore negating user bias. The change in the mean
combined neurological score (the sum of the neurological score
recorded for left and right hind limbs) for malemice inall four groups
from 41 days of age, is plotted in Figure 3A. Neurological score curves
for all male groups were largely similar in shape. Specifically, scores
remained low and fairly constant until approximately 104 days of age
when they began to sharply increase, indicating the onset of
neurological symptoms. This timepoint is approximately 14 days
later than the onset of weight loss shown in Figure 2A, indicating that
weight loss precedes overt neurological pathology in our SOD1
G93A
mice. As has previously been described [29,30], we classified the
definitive onset of symptomatic neurological disease as the time point
at which a mouse reached a neurological score of two in both
hindlimbs. Comparison of the timepoint at which this occurred in all
four males groups revealed no statistically significant differences
(Figure 3B, Table 1).
For humane reasons, a uniform end point of the inability of a
mouse to right itself within 30 s of being placed on a side was used
for all mice in this study. The proportion of male mice surviving
over time is shown in (Figure 3C). There were no statistically
significant differences in survival between any groups indicating
that metformin had no effect on survival in male mice (Table 1).
Metformin treatment negatively affected disease onset
and progression in female mice in a dose-dependent
fashion. Four groups of 15 female mice that were balanced
for age, litter and bodyweight were enrolled in this study. The
average starting bodyweights for all groups were within 0.5 g of
each other (Control: 16.7 g, 0.5 mg/ml: 16.9 g, 2 mg/ml: 16.8 g
and 5 mg/ml: 17.2 g). Towards the end of the study, one female
mouse from the 0.5 mg/ml group was injured by a fellow cage
mate and was therefore culled. Weight and neurological score data
from this mouse were included in weight and neurological score
plots up to the date at which she became wounded and she was
treated as censored in any Kaplan Meier analyses requiring
information about survival. One further female mouse from the
0.5 mg/ml group showed abnormally rapid weight loss and signs
Figure 2. Effect of metformin on body weight, disease onset and disease progression in male SOD1
G93A mice. (A) Mean group body
weight plotted for male SOD1
G93A mice over time from 35 days of age until the date at which the last death within each individual group occurred. As
mice within groups died at different ages, the final weights of all mice were carried forward when calculating group mean values, until the date at
which the last mouse within each group died. This prevented decomposition of the mean at later stages. Error bars represent standard error of the
mean (SEM). (B) Kaplan-Meier survival plot for time to peak weight (an indicator of disease onset) in male SOD1
G93A mice. (C) Kaplan-Meier survival
plot for time from peak weight to end stage (an indicator of disease progression) in male SOD1
G93A mice. Graphs (A), (B) and (C) present data for male
SOD1
G93A mice in all four experimental groups: Control=green, 0.5 mg/ml metformin=yellow, 2 mg/ml metformin=blue, 5 mg/ml
metformin=red). Results for statistical analyses performed on data presented in (B) and (C) are given in Table 1.
doi:10.1371/journal.pone.0024189.g002
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neurological symptoms. She was therefore culled and classed as
dying a ‘non-ALS death’. Weight and neurological score data from
this mouse were not included weight and neurological score plots
and she was treated as censored in all Kaplan Meier analyses.
The change in mean body weight over time for female mice in
all four groups is plotted in Figure 4A from 35 days onwards. As
with male mice, weight curves for all groups showed a very similar
shape, with the onset of weight decline occurring at approximately
90 days of age. However, female mice in the 0.5 mg/ml group
tended to be heavier than mice in other groups between 55 and
135 days of age and female mice in the control group tended to
drop to lower weights at end stage than mice in treatment groups.
As with male mice, no significant differences were seen between
female groups in the time taken to reach peak weight (Figure 4B,
Table 2) but unlike male mice, there was a significant association
between increasing metformin dose and decreasing time from peak
weight to end stage in female mice (Figure 4C, Table 2,
P=0.0362). This indicates that metformin had a negative effect
on disease progression in female mice.
The change in the mean combined neurological score (the sum
of the neurological score recorded for left and right hind limbs) for
female mice in all four groups from 41 days of age, is plotted in
Figure 5A. Neurological score curves for female mice in all groups
were similar in shape until approximately 104 days of age when, as
with male mice, the onset of neurological symptoms began.
Following this point, however, neurological score curves began to
rise more steeply with increasing metformin dose, suggesting a
negative effect of metformin on disease progression. In support of
this there was a significant association between increasing
metformin dose and the time point at which female mice reached
a score of 2 in both hindlimbs (the definitive onset of symptomatic
disease) (Figure 5B, Table 2, P=0.0236).
The proportion of female mice surviving over time is shown in
(Figure 5C). Although there were no significant differences in
survival between groups (Table 2), there was a trend towards
increasing survival with decreasing metformin dose.
Discussion
ALS is a devastating neurodegenerative disorder that is in
desperate need of suitable treatments. Consequently, FDA-
approved drugs that are routinely used for the treatment of other
diseases, represent attractive candidates for research as potential
ALS therapeutics, as their previous safety, toxicity and pharma-
cological testing would speed up their passage into clinical trial
[33]. Metformin is a routinely used anti-type II diabetes drug,
which has been shown to have anti-inflammatory and antioxidant
properties as well as the ability to bring about mitochondrial
biogenesis. In recent years, metformin has been shown to
attenuate pathology in mouse models of both Huntington’s disease
[16] and multiple sclerosis [19] which, like ALS models, show
central nervous system (CNS)-based inflammation, oxidative stress
and mitochondrial abnormalities [4,17,18]. We therefore hy-
pothesised that metformin would also attenuate pathology in the
SOD1
G93A mouse model of ALS. We tested this hypothesis
through an initial study involving the measurement of motor unit
number in the TA and EDL muscles of treated mice at the
symptomatic timepoint of 100 days of age and then performed a
dose-response survival study with longitudinal tracking of disease
progression to further assess the potential of metformin for ALS
therapy.
The ultimate cause of death in SOD1
G93A mice is the retraction
of distal motor axons and denervation of skeletal muscles [34,35].
In light of this, bringing about the preservation of functional motor
units, in which the motor neuron is not only present but also
forming functional neuromuscular junctions, is likely to be critical
when trying to reduce the severity of disease pathology in these
animals. We therefore reasoned that analysis of the effect of
metformin treatment from 35 days of age, on functional motor
unit survival at the symptomatic time point of 100 days of age,
would provide a good indication of the potential neuroprotective
properties of this drug. In these investigations we observed a
significant increase in the survival of functional motor units as
measured by in vivo electrophysiology, in metformin-treated male
EDL muscles (24+/22 vs. 14+/22 motor units, p,0.005) as well
as in metformin-treated female TA muscles (21+/21 vs. 15+/22
motor units, P=0.0134). A strong trend towards increased motor
unit survival was also observed in female EDL muscles and male
TA muscles. We have previously determined the number of
functional motor units in wild type (WT) male EDL muscles at 100
days of age to be 54+/24 (n=6). The increase in the survival of
functional motor units seen in the EDL muscles of metformin-
treated male mice therefore represented a moderate increase from
approximately 26% of WT motor units to 44%. The number of
Table 1. Kaplan Meier time to event analyses for male SOD1
G93A mice.
1,2,3
Median Value (days) P Value
Control 0.5 mg/ml 2 mg/ml 5 mg/ml Log- rank
Log-rank
test for trend
Time to peak weight 89 88 89 89.5 0.8469 0.8492
Time from peak weight to end stage 38.5 44 39 40 0.6986 0.8963
Time to reach score 2 in both hindlimbs 114 121 114.5 114 0.6942 0.6289
Survival 123 128 126 126 0.8575 0.6597
1The Logrank test investigates the null hypothesis that that the Kaplan Meier curves for all groups are identical (i.e. that the treatment did not change the time taken to
reach the event being analysed). Low P-values are therefore indicative of differences between curves that did not occur due to chance. The threshold for significance
was set at P,0.05.
2To perform the log-rank test for trend, experimental groups were arranged in order of increasing dose (Control, then 0,5 mg/ml, 2 mg/ml and 5 mg/ml) and a P value
testing the null hypothesis that there was no linear trend between group order and median time to event was then calculated. Low P-values are indicativeo fa
significant trend between increasing dose and the event being analysed. The threshold for significance was set at P,0.05.
3The time at which peak body weight occurred for each mouse was analysed after spline smoothing of each animal’s body weight values over time (using Prism5
software) from the start of the study to the time at which the mouse died. If the smoothed body weight curve for an individual mouse had multiple equal peaks, the
time point at which the final peak occurred was taken.
doi:10.1371/journal.pone.0024189.t001
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determined by Hegedus et al., to be 95+/212.4 [36]. The increase
in survival of functional motor units seen in the TA muscles of
metformin-treated female mice therefore represented a smaller
increase from approximately 16% of WT motor units to 22%.
Although these increases in motor unit survival seen were not
sufficient to restore motor unit numbers to levels comparable to
WT, they suggested that metformin was having a trophic effect on
motor neuron health in SOD1
G93A mice at 100 days of age and
highlighted the possibility that motor unit survival may be further
enhanced with a different dose of metformin. This led us to
perform a dose response, survival study to investigate the effects of
metformin on disease onset, progression and survival in these
mice.
Despite successful results being documented for many thera-
peutics tested in the SOD1
G93A mouse, Riluzole has been the only
drug to show any, albeit small, beneficial effect in ALS patients
[37]. Investigations into the potential reasons for this disparity
have revealed several confounding variables that may lead to false
positives in experiments in SOD1
G93A mice [22]. These variables
include, in order of impact: the occurrence of non-ALS deaths, the
incidence of low copy transgenics, genetic background or
epigenetic influences causing littermate clustering and a slight
gender effect [22]. Identification of these variables has lead to the
production of guidelines for the preclinical testing of therapeutics
for ALS, which aim to control for these variables and increase
study validity [22,38]. We carefully followed these guidelines in
order to ensure as far as possible, the accurate determination of the
potential of metformin as a therapy for ALS. Specifically in order
to control for the variability introduced by non-ALS deaths, we
closely monitored the health of all mice throughout the study and
excluded relevant data from any mice observed to experience a
non-ALS death. We checked the copy number of any mice
displaying outlying disease progression or survival characteristics
by Q-PCR [27] and were prepared to exclude any mice which had
lost copies of the transgene (although no mice with fewer copies
Figure 3. Effect of metformin on neurological score, neurological disease onset and survival in male SOD1
G93A mice. (A) Mean group
combined neurological score plotted for male SOD1
G93A mice over time from 41 days of age until the date at which the last death within each group
occurred. Combined neurological score was calculated for each mouse at each time point through summation of the neurological scores recorded for
its left and right hindlimbs. As mice within groups died at different ages, the final combined neurological scores of all mice were carried forward
when calculating group mean values, until the date at which the last mouse within each group died. This prevented decomposition of the mean at
later stages. Error bars represent standard error of the mean (SEM). (B) Kaplan-Meier survival plot for the time taken for male SOD1
G93A mice to reach a
neurological score of 2 in both hindlimbs (an indicator of the onset of symptomatic neurological disease). (C) Kaplan-Meier survival plot for the time
taken for male SOD1
G93A mice to reach the humane end stage of attaining a neurological score of 4 (representative of survival). Graphs (A), (B) and (C)
present data for male SOD1
G93A mice in all four experimental groups: Control=green, 0.5 mg/ml metformin=yellow, 2 mg/ml metformin=blue,
5 mg/ml metformin=red). Results for statistical analyses performed on data presented in (B) and (C) are given in Table 1.
doi:10.1371/journal.pone.0024189.g003
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performed with mice on a mixed-hybrid genetic background. Mice
on backgrounds such as this show a greater variability than those
from inbred strains [39] and therefore it was essential that we
controlled for the effects of litter clustering in order to produce
meaningful results. Scott et al., confirmed using a specially
designed computer model (SimLIMS) and data from 2241 control
SOD1
G93A mice on a mixed hybrid genetic background
(maintained by breeding hemizygous B6SJLTg (SOD1
G93A) males
to B6SJLF1 dams), that with an n-number of 24 mice per cohort
(12 males and 12 females), and the employment of same-gender
litter matching as well as exclusion of mice experiencing non-ALS
deaths or loss of transgene copies, noise within the experiment
could be reduced to a virtual zero [22]. We were careful to meet
these requirements and are therefore confident that our results are
meaningful.
Despite seeing small but significant increases in motor unit
survival with metformin treatment in our initial investigations, we
were unable to detect any significant effect of metformin treatment
on disease onset, progression or survival in male or female
SOD1
G93A mice at any of the doses tested in our survival study.
This suggests that at the early symptomatic timepoint of 100 days
of age, when motor unit survival was measured in our initial study,
metformin-induced beneficial effects outweighed any toxic effects
and were therefore able to augment disease pathology. However,
at later time points, metformin induced trophic effects may have
been overshadowed by advancing and aggressive SOD1
G93A
pathology and potentially negative drug effects. This highlights
that experiments which provide a ‘snapshot’ of pathology at a
particular time point, should always be backed up with robust
survival studies including longitudinal monitoring of disease
progression, before drugs are put forward for clinical trial.
Metformin has previously been shown to have anti-inflamma-
tory and anti-oxidant properties as well as the ability to bring
about mitochondrial biogenesis and these effects are likely to have
contributed to the increased motor unit survival seen in our initial
study. However, this drug has been identified as having many
other cellular effects in addition to these and some of these could
have been detrimental in SOD1
G93A mice and prevented longterm
attenuation of motor unit loss. For example, metformin has been
Figure 4. Effect of metformin on body weight, disease onset and disease progression in female SOD1
G93A mice. (A) Mean group body
weight plotted for female SOD1
G93A mice over time from 35 days of age until the date at which the last death within each individual group occurred.
As mice within groups died at different ages, the final weights of all mice were carried forward when calculating group mean values, until the date at
which the last mouse within each group died. This prevented decomposition of the mean at later stages. Error bars represent the standard error of
the mean (SEM). (B) Kaplan-Meier survival plot for time to peak weight (an indicator of disease onset) in female SOD1
G93A mice. (C) Kaplan-Meier
survival plot for time from peak weight to end stage (an indicator of disease progression) in female SOD1
G93A mice. Graphs (A), (B) and (C) present
data for female SOD1
G93A mice in all four experimental groups: Control=green, 0.5 mg/ml metformin=yellow, 2 mg/ml metformin=blue, 5 mg/ml
metformin=red). Results for statistical analyses performed on data presented in (B) and (C) are given in Table 2.
doi:10.1371/journal.pone.0024189.g004
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compromised as a result of ALS pathology [41] and also to bring
about a reduction in both total-and LDL-cholesterol levels, high
levels of which have paradoxically been shown to be a positive
prognostic factor in ALS patients [42].
In our survival study we were surprised to observe a significant
association between increasing metformin dose and both the onset
of symptomatic neurological disease and disease progression in
female SOD1
G93A mice. This suggests that metformin may have
interacted in a negative fashion with a female specific cellular
process that is normally beneficial for motor neuron health. It is
well documented that female SOD1
G93A mice develop neurolog-
ical symptoms later and have a longer lifespan than male
SOD1
G93A mice and this was also found to be the case in our
study (Figure S1A and B, Tables S1 and S2). Specifically, median
onset of symptomatic neurological disease was 18 days later in
control female mice than in their male counterparts (132 vs. 114,
P=0.0001) and median survival was extended by 17 days (140 vs.
123, P=0.0011). Interestingly, prevention of oestrogen production
in female SOD1
G93A mice via ovariectomy has been shown to
accelerate disease progression [31] and also to reduce survival time
to levels comparable to male SOD1
G93A mice [31,43]. Further-
more treatment of these ovariectomised females with 17b-
oestradiol has been shown to rescue these effects [31]. This
suggests that the presence of oestrogen is a large contributing
factor to the slower disease progression and increased lifespan of
female SOD1
G93A mice compared to males. Metformin is
increasingly becoming prescribed for the treatment of polycystic
ovary syndrome (PCOS [OMIM 184700]) with the aim of
reducing the insulin resistance that is associated with the disorder.
Interestingly, it has recently been identified that metformin is also
able to inhibit basal and insulin-stimulated 17b-ostradiol (E2)
production and that this may contribute to its beneficial effect in
PCOS [44,45]. In light of the trophic effect of oestrogen on disease
progression and survival in female SOD1
G93A mice and the
documented ability of metformin to inhibit oestrogen production,
Figure 5. Effect of metformin on neurological score, neurological disease onset and survival in female SOD1
G93A mice. (A) Mean
group combined neurological score plotted for female SOD1
G93A mice over time from 41 days of age until the date at which the last death within
each group occurred. Combined neurological score was calculated for each mouse at each time point through summation of the neurological scores
recorded for its left and right hindlimbs. As mice within groups died at different ages, the final combined neurological scores of all mice were carried
forward when calculating group mean values, until the date at which the last mouse within each group died. This prevented decomposition of the
mean at later stages. Error bars represent standard error of the mean (SEM). (B) Kaplan-Meier survival plot for the time taken for female SOD1
G93A
mice to reach a neurological score of 2 in both hindlimbs (an indicator of the onset of symptomatic neurological disease). (C) Kaplan-Meier survival
plot for the time taken for female SOD1
G93A mice to reach the humane end stage of attaining a neurological score of 4 (representative of survival).
Graphs (A), (B) and (C) present data for female SOD1
G93A mice in all four experimental groups: Control=green, 0.5 mg/ml metformin=yellow, 2 mg/
ml metformin=blue, 5 mg/ml metformin=red). Results for statistical analyses performed on data presented in (B) and (C) are given in Table 2.
doi:10.1371/journal.pone.0024189.g005
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mice in our study were at least in part derived from reduced
oestrogen production. In support of this, treatment of female
SOD1
G93A mice with either 2 or 5 mg/ml metformin, prevented
the significant delay in the onset of symptomatic neurological
disease seen in female control mice compared to male control mice
(Figure S1A, Table S2). Furthermore, treatment of female
SOD1
G93A mice with metformin at all doses negated the
significant increase in survival seen in female control mice
compared to male control mice and this effect became more
pronounced with increasing metformin dose (Figure S1B, Table
S2).
In conclusion, we have shown that despite showing promise in
mouse models of Huntington’s disease and multiple sclerosis, which
share many pathological processes with SOD1
G93A mice, metfor-
min is not capable of delaying disease onset, slowing disease
progression or increasing survival in these animals. Furthermore,
metformin appears to be harmful in female SOD1
G93A mice in a
dose dependent fashion and this effect may be derived from its
ability to inhibit oestrogen production. Thiscould have implications
for the prescription of medication to female ALS patients suffering
from type II diabetes as metformin could potentially worsen their
prognosis. However this situation is likely to be complex as a recent
retrospective study of ALS patients with pre-morbid diabetes
mellitus has suggested a positive effect of diabetes on age of ALS
onset [46]. Further investigations into the relationship between ALS
and diabetes and the way in which metformin treatment modifies
this relationship are therefore required. Finally, the disparity
between the observed ability of metformin to moderately increase
motor unit survival in our initial investigations and the inability of
this beneficial effect to be translated into delayed disease onset and
progression or increased survival, highlights that studies analyzing
the effect of a drug at a single time point are alone not sufficient to
warrant the testing of this drug in the ALS clinic.
Supporting Information
Figure S1 Kaplan-Meier time to event plots for (A) time taken
for mice to reach a score of 2 in both hindlimbs (the definitive
onset of symptomatic neurological disease) and (B) time taken for
mice to reach the humane end stage of the inability to right within
30 s of being placed on a side (survival) for all female groups and
the male control group. Female mice were treated with normal
drinking water (control, green) or 0.5 (yellow), 2 (blue) or 5 (red)
mg/ml metformin in the drinking water from 35 days of age. Male
control mice (black) received normal drinking water throughout.
(TIF)
Table S1 Median values derived from Kaplan Meier analyses
for the time taken for mice to reach a score of 2 in both hindlimbs
and the time taken for mice to reach the humane end stage of the
inability to right within 30 s of being placed on a side (survival) for
all female groups (control, 0.5, 2 and 5 mg/ml metformin) and the
male control group.
(DOC)
Table S2 Summary of statistical analyses performed to compare
the time taken for mice to reach a score of 2 in both hindlimbs and
the timetakenformicetoreachthehumaneendstage oftheinability
to right within 30 s of being placed on a side in all experimental
groups.The Logrank test investigates the null hypothesis that that the
Kaplan Meier curves for all groups are identical. Low P-values are
therefore indicative of differences between groups that did not occur
due to chance. Statistical comparison of the time taken for mice to
reach a score of 2 in both hindlimbs and the time taken for mice to
reach the humane end stage (survival) in all four male and female
groups via a log rank test revealed that there were significant
differences between the groups for both measures. The threshold for
significance was set at P,0.05 for these comparisons. Subsequent
post hoc comparisons between pairs of groups for both measures
were then performed. Using Bonferroni’s correction for multiple
comparisons we calculated that P must be less than 0.0018 (i.e.
P=,0.05/28, where 28 represents the number of possible pairwise
comparisons for 8 different experimental groups) in order to be
significant in these pairwise comparisons.
(DOC)
Method S1 Genotyping and copy number assessment.
(DOC)
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